Select the organ preservation pathway you wish to evaluate
For muscle-invasive bladder cancer (MIBC): assess suitability for Bipolar ESD en-bloc resection + EV+P immunotherapy + MR-Linac/Proton therapy. Based on EV-PRIME and KEYNOTE-905 trial data.
For prostate cancer: assess suitability for MR-Linac SBRT or ultra-hypofractionated proton therapy (5 fractions) with Barrigel hydrogel rectal protection.